Build your next asset decision on evidence you can defend.
Show investors and partners that your asset can launch. We map the evidence and the ecosystem around your programme, test the assumptions that matter, and give you a clear, source-linked view of what is known and what still needs proof.
When the next milestone puts your rationale under scrutiny
Partnering discussions, indication selection and development milestones all invite the same questions: what does the disease evidence actually support, and where is the rationale resting on assumption?
Small teams rarely have time to trace every claim back to its source. We help you see which parts of your story are well supported, which are contested, and which still need work, before a partner or board asks.
Three questions an engagement can answer
- 1
Which findings support our indication and development rationale?
- 2
How do clinicians, payers and patients weigh each attribute of our target product profile?
- 3
Which evidence gaps should we close before partnering or the next milestone?
Start with the landscape. Go deeper where it matters.
Rare disease landscaping, country by country with a European lens. Usually 6 to 10 weeks to a first edition.
- Epidemiology
- Competitor activity
- Diagnosis, treatment and referral pathways
- KOLs and the specialists who matter
- Effectiveness of current products
- Country-specific patient journey
- Guidelines, and who writes them
- Stakeholders who influence decisions
New views on the same evidence layer
TPP simulation
Test profile options against the evidence and stakeholder views.
Therapy and diagnostic watch list
Competing programmes and tests, tracked and sourced.
HTA evidence readiness
What payers will ask, and what is still missing.
Advisory board input
Open questions, and where experts disagree.
What you could receive
- Source-linked disease evidence brief
- Evidence-gap and assumption register
- Expert interpretation of material uncertainties
- Questions for further research and stakeholder discussions
Proposed deliverables. The final set is agreed in scope for each engagement.
Evidence and expert interpretation, kept distinct
AI-assisted mapping covers publications, clinical trials, congresses, guidelines, registries, approvals and more. Every claim is linked to its source and date.
Interviews and surveys with clinicians, patient groups and other stakeholders add the real-world view. New findings refine the question.
Our experts review each claim and set out what it means for your programme, kept separate from what the sources say.
Frequently asked questions
Will this tell us whether our asset works?
No. We assess what the disease evidence supports and where it is uncertain. We do not assess efficacy of your asset, and our work does not guarantee partnering success or valuation.
Can we share confidential data with you?
Only once an engagement is agreed and appropriate confidentiality terms are in place. Please do not send confidential materials through the initial contact form.
Is this a software platform we log into?
No. Systemix is an expert-led service. We deliver source-linked findings, registers and interpretation as agreed deliverables for each engagement, not a self-service tool.
Discuss your asset question
Tell us the disease, the asset and the decision ahead. We will come back with what a scoped engagement would cover.